Occlusal disharmonies modulate central catecholaminergic activity in the rat.
Occlusal disharmonies have classically been thought to be involved in the etiopathogenesis of bruxism, as have, more recently, alterations in central neurotransmission, particularly dopaminergic neurotransmission. However, the connection between these two factors has still not been established. In this study, we assessed the effects of diverse occlusal disharmonies, maintained for either 1 day or 14 days, on neurochemical indices of dopaminergic and noradrenergic activity in the striatum, frontal cortex, and hypothalamus of the rat. The in vivo activity of tyrosine hydroxylase, determined as the accumulation of 3,4-dihydroxyphenylalanine (DOPA), 30 min after the administration of 3-hydroxybenzylhydrazine, a DOPA decarboxylase inhibitor, and dopamine and noradrenaline contents were quantified by high-performance liquid chromatography with electrochemical detection. The wearing of an acrylic cap on both lower incisors for 1 day induced a significant increase in DOPA accumulation in the regions analyzed, with parallel increases in dopamine levels in the hypothalamus and dopamine and noradrenaline in the frontal cortex. After the cap was maintained for 14 days, DOPA accumulation tended to return to control values, except in the left striatum, thereby causing an imbalance between hemispheres. In contrast, 1 or 14 days after the lower left and the upper right incisors were cut, less pronounced changes in catecholaminergic neurotransmission were found in the brain areas studied. Moreover, the cutting of one lower incisor did not modify either DOPA accumulation or dopamine and noradrenaline contents in the striatum or hypothalamus. These results provide experimental evidence of a modulation of central catecholaminergic neurotransmission by occlusal disharmonies, being dependent on the nature of the incisal alteration and on the time during which it was maintained.
Areso
M P
MP
Department of Pharmacology, Faculty of Medicine and Odontology, University of the Basque Country, Leioa, Bizkaia, Spain.
Giralt
M T
MT
Sainz
B
B
Prieto
M
M
García-Vallejo
P
P
Gómez
F M
FM
D000704:Analysis of Variance; D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001921:Brain / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000378:metabolism; D003769:Dental Occlusion, Traumatic / Q000378:metabolism*; D004295:Dihydroxyphenylalanine / Q000378:metabolism; D004298:Dopamine / Q000032:analysis; D004563:Electrochemistry; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004837:Epinephrine / Q000032:analysis; D005625:Frontal Lobe / Q000378:metabolism; D006834:Hydrazines / Q000494:pharmacology; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D008310:Malocclusion / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011941:Receptors, Adrenergic / Q000378:metabolism; D017983:Receptors, Catecholamine / Q000378:metabolism*; D011954:Receptors, Dopamine / Q000378:metabolism; D009435:Synaptic Transmission / Q000502:physiology*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D004791:Enzyme Inhibitors; D006834:Hydrazines; D011941:Receptors, Adrenergic; D017983:Receptors, Catecholamine; D011954:Receptors, Dopamine; D004295:Dihydroxyphenylalanine; C004297:3-hydroxybenzylhydrazine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine; D004837:Epinephrine